Bristol Myers’ BMS-986278 yields promising results in slowing pulmonary fibrosis progression in Phase 2 trial

Bristol Myers Squibb (NYSE: BMY) disclosed a pivotal Phase 2 study highlighting that BMS-986278, an investigational oral LPA1 antagonist, reduces the rate of lung function ... Read More